Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The aim of this clinical trial is to investigate the efficacy (by monitoring the wound size
reduction of CVUs) and safety (by monitoring adverse events [AEs]) of three dose groups of
the investigational medicinal product (IMP) allo-APZ2-CVU, topically administered on target
wounds of patients with CVU compared to placebo.